文献速递间质性肺疾病

电子鼻技术在结节病诊断中的表现

Diagnostic Performance of Electronic Nose Technology in Sarcoidosis.
PubMed 文献 · Chest · 2021-10-28

本研究为横断面研究,纳入252例结节病患者、317例间质性肺疾病(ILD)患者和48例健康对照,采用电子鼻(eNose)分析呼出气挥发性有机物。在独立验证队列中,eNose区分结节病与对照的AUC达1.00,区分肺结节病与其他ILD的AUC为0.87,区分肺结节病与过敏性肺炎的AUC为0.88;但结节病不同亚组间呼气谱无显著差异。

要点

  • eNose可准确区分结节病与健康对照(AUC 1.00)及肺结节病与其他ILD(AUC 0.87)。
  • eNose区分肺结节病与过敏性肺炎的AUC为0.88(95%CI 0.75-1.00)。
  • 结节病不同临床亚组间呼气谱无显著差异,但可区分sIL-2R轻度与高度升高者。

核心结论

  • eNose技术可区分结节病与ILD及健康对照,可能有助于未来实现无创精准诊断。

研究设计与样本

  • 横断面研究,纳入252例结节病患者、317例ILD患者和48例健康对照。
  • 使用SpiroNose电子鼻分析呼出气,采用偏最小二乘判别分析和ROC分析,并在训练集和独立验证集中评估。

主要发现

  • 验证队列中,eNose区分结节病与对照的AUC为1.00。
  • 区分肺结节病与其他ILD的AUC为0.87(95%CI 0.82-0.93),与过敏性肺炎的AUC为0.88(95%CI 0.75-1.00)。
  • 结节病有无肺受累、肺纤维化、多器官受累、病理支持诊断及免疫抑制治疗组间呼气谱无显著差异。
  • sIL-2R轻度与高度升高组间呼气谱有差异,中位cutoff为772.0 U/mL,AUC为0.78(95%CI 0.64-0.92)。

临床怎么用

  • eNose可作为结节病无创诊断的潜在辅助工具,尤其用于区分结节病与其他ILD。
  • 对sIL-2R升高程度不同的结节病患者,eNose或有助于识别疾病活动度差异。

局限性

  • 研究为横断面设计,eNose在监测结节病活动度中的价值尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diagnosing sarcoidosis can be challenging, and a noninvasive diagnostic method is lacking. The electronic nose (eNose) technology profiles volatile organic compounds in exhaled breath and has potential as a point-of-care diagnostic tool. RESEARCH QUESTION: Can eNose technology be used to distinguish accurately between sarcoidosis, interstitial lung disease (ILD), and healthy control subjects, and between sarcoidosis subgroups? STUDY DESIGN AND METHODS: In this cross-sectional study, exhaled breath of patients with sarcoidosis and ILD and healthy control subjects was analyzed by using an eNose (SpiroNose). Clinical characteristics were collected from medical files. Partial least squares discriminant and receiver-operating characteristic analyses were applied to a training and independent validation cohort. RESULTS: The study included 252 patients with sarcoidosis, 317 with ILD, and 48 healthy control subjects. In the validation cohorts, eNose distinguished sarcoidosis from control subjects with an area under the curve (AUC) of 1.00 and pulmonary sarcoidosis from other ILD (AUC, 0.87; 95% CI, 0.82-0.93) and hypersensitivity pneumonitis (AUC, 0.88; 95% CI, 0.75-1.00). Exhaled breath of sarcoidosis patients with and without pulmonary involvement, pulmonary fibrosis, multiple organ involvement, pathology-supported diagnosis, and immunosuppressive treatment revealed no distinctive differences. Breath profiles differed between patients with a slightly and highly elevated soluble IL-2 receptor level (median cutoff, 772.0 U/mL; AUC, 0.78; 95% CI, 0.64-0.92). INTERPRETATION: Patients with sarcoidosis can be distinguished from ILD and healthy control subjects by using eNose technology, indicating that this method may facilitate accurate diagnosis in the future. Further research is warranted to understand the value of eNose in monitoring sarcoidosis activity.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. van der Sar IG, Moor CC, Oppenheimer JC, et al. Diagnostic Performance of Electronic Nose Technology in Sarcoidosis. Chest. 2021. PMID: 34756945. doi:10.1016/j.chest.2021.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。